Literature DB >> 16651414

Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

François Bertucci1, Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Emilie Mamessier, José Adélaïde, Stéphane Debono, Gilles Houvenaeghel, Dominique Maraninchi, Patrice Viens, Colette Charpin, Jocelyne Jacquemier, Daniel Birnbaum.   

Abstract

Medullary breast cancer (MBC) is a rare but enigmatic pathologic type of breast cancer. Despite features of aggressiveness, MBC is associated with a favorable prognosis. Morphologic diagnosis remains difficult in many cases. Very little is known about the molecular alterations involved in MBC. Notably, it is not clear whether MBC and ductal breast cancer (DBC) represent molecularly distinct entities and what genes/proteins might account for their differences. Using whole-genome oligonucleotide microarrays, we compared gene expression profiles of 22 MBCs and 44 grade III DBCs. We show that MBCs are less heterogeneous than DBCs. Whereas different molecular subtypes (luminal A, luminal B, basal, ERBB2-overexpressing, and normal-like) exist in DBCs, 95% MBCs display a basal profile, similar to that of basal DBCs. Supervised analysis identified gene expression signatures that discriminated MBCs from DBCs. Discriminator genes are associated with various cellular processes related to MBC features, in particular immune reaction and apoptosis. As compared with MBCs, basal DBCs overexpress genes involved in smooth muscle cell differentiation, suggesting that MBCs are a distinct subgroup of basal breast cancer with limited myoepithelial differentiation. Finally, MBCs overexpress a series of genes located on the 12p13 and 6p21 chromosomal regions known to contain pluripotency genes. Our results contribute to a better understanding of MBC and of mammary oncogenesis in general.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651414     DOI: 10.1158/0008-5472.CAN-06-0031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

Review 1.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

2.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 3.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 4.  Molecular profiling in breast cancer.

Authors:  Shannon R Morris; Lisa A Carey
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

Review 5.  Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Konstantinos Nikolettos; Dimitrios Dimitroulis; Evangelos Diamantis; Paraskevi Farmaki; Alexandros Patsouras; Errika Voutyritsa; Athanasios Syllaios; Constantinos G Zografos; Efstathios A Antoniou; Nikos Nikolettos; Alkiviadis Kostakis; Konstantinos Kontzoglou; Dimitrios Schizas; Afroditi Nonni
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 6.  Unraveling the microenvironmental influences on the normal mammary gland and breast cancer.

Authors:  Britta Weigelt; Mina J Bissell
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

7.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.

Authors:  Marise R Heerma van Voss; Petra van der Groep; Jos Bart; Elsken van der Wall; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-04-16       Impact factor: 4.430

9.  Neighborhood rough set reduction-based gene selection and prioritization for gene expression profile analysis and molecular cancer classification.

Authors:  Mei-Ling Hou; Shu-Lin Wang; Xue-Ling Li; Ying-Ke Lei
Journal:  J Biomed Biotechnol       Date:  2010-06-23

10.  Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.

Authors:  R Fernández-Ramires; X Solé; L De Cecco; G Llort; A Cazorla; N Bonifaci; M J Garcia; T Caldés; I Blanco; M Gariboldi; M A Pierotti; M A Pujana; J Benítez; A Osorio
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.